The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (PD-L1) on antigen-presenting cells (APCs), is a major mechanism of tumor immune evasion. PD-1 and PD-L1 blockade antibodies have produced remarkable clinical activities against a subset of cancers. Binding between T cell-intrinsic PD-1 and APC-intrinsic PD-L1 triggers inhibitory signaling to attenuate the T cell response. Here, we report that PD-1 is co-expressed with PD-L1 on tumor cells and tumor-infiltrating APCs. Using reconstitution and cell culture assays, we demonstrate that the co-expressed PD-1 binds to PD-L1 in cis. Such interaction inhibits the ability of PD-L1 to bind T cell-intrinsic PD-1 in trans and, in turn, repress...
Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cance...
Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively documented, ...
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activ...
The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (PD-L...
Abstract Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the...
PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1...
Cancer therapies: More to PD-L1 than meets the T cell Programmed cell death-1 ligand-1 (PD-L1) favor...
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune checkpoints wi...
Background: The clinical benefit of immunotherapeutic approaches against cancer has been well establ...
The novel antibody-based immunotherapy in oncology exploits the activation of immune system mediated...
The PD-L1/PD-1 axis mediates immune tolerance and promotes tumor growth and progression via the inhi...
Immunotherapy based on monoclonal antibodies targeting the immune checkpoints PD-1 and PD-L1 has rev...
Although the immune checkpoint role of programmed death ligand 1 (PD-L1) has been established and ta...
PD-L1 on the surface of tumor cells binds its receptor PD-1 on effector T cells, thereby suppre...
PD-1 (Programmed Death Receptor-1) is a cell membrane protein found on Cytotoxic T cells (CTLs) surf...
Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cance...
Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively documented, ...
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activ...
The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (PD-L...
Abstract Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the...
PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1...
Cancer therapies: More to PD-L1 than meets the T cell Programmed cell death-1 ligand-1 (PD-L1) favor...
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune checkpoints wi...
Background: The clinical benefit of immunotherapeutic approaches against cancer has been well establ...
The novel antibody-based immunotherapy in oncology exploits the activation of immune system mediated...
The PD-L1/PD-1 axis mediates immune tolerance and promotes tumor growth and progression via the inhi...
Immunotherapy based on monoclonal antibodies targeting the immune checkpoints PD-1 and PD-L1 has rev...
Although the immune checkpoint role of programmed death ligand 1 (PD-L1) has been established and ta...
PD-L1 on the surface of tumor cells binds its receptor PD-1 on effector T cells, thereby suppre...
PD-1 (Programmed Death Receptor-1) is a cell membrane protein found on Cytotoxic T cells (CTLs) surf...
Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cance...
Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively documented, ...
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activ...